Group Antenatal Healthcare, Education, and Recovery (GATHER)

November 13, 2026 updated by: Thomas Jefferson University

The objective is to evaluate implementation strategies and effectiveness of group prenatal care for women in treatment for opioid use disorder.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

110

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Vanessa Short
  • Phone Number: 215-955-8429

Study Locations

    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Recruiting
        • Thomas Jefferson University
        • Contact:
        • Principal Investigator:
          • Vanessa Short, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria

  • at least 18 years of age
  • pregnant and less than 28 weeks of gestation at study enrollment
  • receiving treatment for OUD
  • no major antepartum complications
  • capable of giving informed consent
  • willing to be visited by research personnel for up to 12 months post-delivery.

Exclusion Criteria:

  • inability to speak English
  • medical complications of pregnancy which would preclude participation in group care.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group Prenatal Care

group prenatal care

Patients will be grouped with other women who are all due to deliver around the same time and receive their routine PNC together during 2-hour group sessions. During the first 30-60 minutes of each group session, patients will measure and record their own weight and blood pressure, and an OB healthcare provider (facilitator) will conduct a brief physical assessment in a private area. This 1-on-1 time is also used for the patient to discuss any private concerns that the patient does not feel to disclose to the group. Following the individual health assessments, the OB provider, co-facilitators, and patients will sit in circle for a discussion. There are a range of educational topics set for each of the ten group sessions, and the content is generally tailored to the participants' gestational age or the age of their infants. Any required blood draws and immunizations will be given at the last 30 minutes of the session, if applicable.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maternal healthcare engagement
Time Frame: from enrollment to delivery

Proportion of expected PNC visit attended

from enrollment to delivery
OUD treatment retention
Time Frame: from enrollment to delivery

OUD treatment retention

from enrollment to delivery
Opioid abstinence
Time Frame: from enrollment to delivery

Percentage of urine/blood/saliva toxicology testing negative for unauthorized opioids and other drugs during pregnancy

from enrollment to delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

August 1, 2030

Study Registration Dates

First Submitted

October 27, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2026-15 TJU
  • 083-CC101702-Z19603 (Other Grant/Funding Number: Westat)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.